Breaking News Instant updates and real-time market news.

NITE

Nightstar Therapeutics

$25.50

0.01 (0.04%)

, BIIB

Biogen

$232.40

-1.99 (-0.85%)

08:40
04/16/19
04/16
08:40
04/16/19
08:40

Nightstar Therapeutics reports expiration of HSR waiting period

Nightstar Therapeutics (NITE) announced the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, with respect to the recommended acquisition of the entire issued and to be issued share capital of Nightstar by Tungsten Bidco Limited, a newly-incorporated company and wholly-owned subsidiary of Biogen Switzerland Holdings GmbH (BIIB). Nightstar has also received notice from Bidco's representatives that the German Federal Cartel Office will not assert jurisdiction to review the Acquisition. Therefore, Condition C set out in Part III of the scheme document dated April 9 relating to the Acquisition has been satisfied. The Scheme is expected to become effective on June 7.

NITE

Nightstar Therapeutics

$25.50

0.01 (0.04%)

BIIB

Biogen

$232.40

-1.99 (-0.85%)

  • 24

    Apr

  • 30

    Apr

  • 01

    May

  • 29

    May

NITE Nightstar Therapeutics
$25.50

0.01 (0.04%)

03/05/19
UBSW
03/05/19
DOWNGRADE
Target $25.5
UBSW
Neutral
Nightstar Therapeutics downgraded to Neutral from Buy at UBS
UBS analyst Carter Gould downgraded Nightstar Therapeutics (NITE) to Neutral on the announced takeover by Biogen (BIIB). The analyst raised his price target for the shares to $25.50 from $21.
03/05/19
MZHO
03/05/19
DOWNGRADE
Target $25.5
MZHO
Neutral
Nightstar Therapeutics downgraded to Neutral from Buy at Mizuho
Mizuho analyst Difei Yang downgraded Nightstar Therapeutics (NITE) to Neutral while raising her price target for the shares to $25.50 from $22. The analyst believes the takeover by Biogen (BIIB) properly values Nightstar.
03/20/19
MZHO
03/20/19
NO CHANGE
Target $416
MZHO
Buy
Biogen likely not done with gene therapy acquisitions, says Mizuho
After meeting with management, Mizuho analyst Salim Syed believes Biogen (BIIB) is not done with deals in the gene therapy space. The company continues to like the space and does not view the Nightstar Therapeutics (NITE) acquisition as fulfilling its desire to have a gene therapy platform, Syed tells investors in a research note. The analyst keeps a Buy rating on Biogen shares with a $416 price target.
03/25/19
LEHM
03/25/19
DOWNGRADE
Target $26
LEHM
Equal Weight
Nightstar Therapeutics downgraded to Equal Weight from Overweight at Barclays
Barclays analyst Gena Wang downgraded Nightstar Therapeutics to Equal Weight from Overweight and lowered her price target for the shares to $26 from $28. The analyst cites the pending takeover by Biogen (BIIB) for the downgrade.
BIIB Biogen
$232.40

-1.99 (-0.85%)

03/26/19
PIPR
03/26/19
NO CHANGE
Target $280
PIPR
Overweight
Piper continues to recommend Biogen shares after deeper dive on BIIB067
Piper Jaffray analyst Christopher Raymond continues to recommend Biogen shares after a deeper dive on BIIB067, an anti-sense oligonucleotide targeting SOD1 for the treatment of SOD1-amyotrophic lateral sclerosis. With the recent discontinuation of aducanumab in mild Alzheimer's disease, the company's amyotrophic lateral sclerosis anti-sense oligonucleotide programs could help dispel the notion that Biogen has no pipeline, Raymond tells investors in a research note. He thinks the BIIB067 and BIIB078 programs could add $10 and $15, respectively, to the stock if successful. Raymond keeps an Overweight rating on Biogen with a $280 price target. The stock closed yesterday up $3.55 to $220.26.
04/02/19
PIPR
04/02/19
NO CHANGE
PIPR
Overweight
Piper says AAN meeting should be 'meaningful' for Alexion, Biogen
Piper Jaffray analyst Christopher Raymond reported that the American Academy of Neurology posted emerging science abstract titles this morning, adding that full abstracts are not anticipated until May 3. It appears Phase 3 data on Alexion's (ALXN) Soliris for Neuromyelitis Optica Spectrum Disorder, or NMOSD, will be presented as an emerging science abstract and that data from a Phase 1/2 study of Biogen's (BIIB) BIIB067 in SOD1 mutant ALS patients will also be presented, making the meeting potentially "meaningful" for both. Raymond keeps Overweight ratings on Alexion and Biogen.
04/10/19
RAJA
04/10/19
INITIATION
RAJA
Market Perform
Biogen resumed with a Market Perform at Raymond James
Raymond James analyst Steven Seedhouse resumed coverage of Biogen with a Market Perform rating, stating that the company's remaining business following the failure of aducanumab "appears a little fragile" and faces "existential risk" in some cases, such as the Tecfidera IPR decision due in 2020. Near-term pipeline readouts, including the nearest readouts on Vumerity and BIIB067, don't seem high-impact enough to reverse sentiment, Seedhouse tells investors.
04/11/19
BERN
04/11/19
INITIATION
Target $48
BERN
Outperform
PTC Therapeutics initiated with an Outperform at Bernstein
Bernstein analyst Vincent Chen started coverage on PTC Therapeutics (PTCT) with an Outperform rating and a $48 price target, given his positive view on the commercial potential of risdiplam in SMA. The analyst believes that there will still be a substantial market opportunity for non-gene therapy drugs after approval, and thinks risdiplam's oral dosing will be a substantial advantage over Biogen (BIIB) Spinraza's intrathecal administration. If risdiplam is safe and comparably efficacious to Spinraza, Chen forecasts potential for $2.5B in revenues by 2030.

TODAY'S FREE FLY STORIES

CNSL

Consolidated Communications

$6.03

-2.86 (-32.17%)

14:29
04/25/19
04/25
14:29
04/25/19
14:29
Downgrade
Consolidated Communications rating change at Raymond James »

Consolidated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 29

    Apr

BB

BlackBerry

$9.11

0.205 (2.30%)

14:25
04/25/19
04/25
14:25
04/25/19
14:25
Options
BlackBerry call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    May

  • 16

    May

  • 17

    May

TSLA

Tesla

$247.99

-10.71 (-4.14%)

14:24
04/25/19
04/25
14:24
04/25/19
14:24
Hot Stocks
Tesla to delay $1,000 full self-driving price hike until May 10, CEO says »

Tesla CEO Elon Musk…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

YUMA

Yuma Energy

$0.47

0.1991 (72.40%)

14:22
04/25/19
04/25
14:22
04/25/19
14:22
Hot Stocks
Breaking Hot Stocks news story on Yuma Energy »

Yuma Energy trading…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WEC

WEC Energy

$78.05

1.09 (1.42%)

14:21
04/25/19
04/25
14:21
04/25/19
14:21
Earnings
WEC Energy sees Q2 EPS 70c-72c, consensus 74c »

Says guidance assumes…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 02

    May

  • 21

    May

MDP

Meredith

$58.39

0.04 (0.07%)

14:19
04/25/19
04/25
14:19
04/25/19
14:19
Periodicals
Breaking Periodicals news story on Meredith »

Authentic Brands in talks…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    May

  • 09

    May

  • 13

    Nov

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

14:17
04/25/19
04/25
14:17
04/25/19
14:17
Technical Analysis
NASDAQ market internals summary »

Volume is above average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CNSL

Consolidated Communications

$6.09

-2.805 (-31.55%)

14:16
04/25/19
04/25
14:16
04/25/19
14:16
Downgrade
Consolidated Communications rating change at Raymond James »

Consolidated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 29

    Apr

$NYE

NYSE Market Internals

$0.00

(0.00%)

14:16
04/25/19
04/25
14:16
04/25/19
14:16
Technical Analysis
NYSE market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WEC

WEC Energy

$77.97

1.01 (1.31%)

14:12
04/25/19
04/25
14:12
04/25/19
14:12
Earnings
WEC Energy sees FY19 EPS at high end of $3.48-$3.52 range, consensus $3.51 »

Says on track to add…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 02

    May

  • 21

    May

F

Ford

$9.41

-0.17 (-1.77%)

, GM

General Motors

$39.12

-0.61 (-1.54%)

14:10
04/25/19
04/25
14:10
04/25/19
14:10
Earnings
Fly Intel: What to watch in auto sector earnings reports »

Ford (F) is scheduled to…

F

Ford

$9.41

-0.17 (-1.77%)

GM

General Motors

$39.12

-0.61 (-1.54%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 25

    Apr

  • 30

    Apr

  • 01

    May

  • 03

    May

  • 09

    May

  • 05

    Jun

  • 24

    Jul

  • 23

    Oct

CPRI

Capri Holdings

$44.85

-1.26 (-2.73%)

14:05
04/25/19
04/25
14:05
04/25/19
14:05
Options
Capri Holdings call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

14:00
04/25/19
04/25
14:00
04/25/19
14:00
General news
Treasury Action: the market has eroded slightly »

Treasury Action: the…

CLB

Core Laboratories

$66.31

-6.595 (-9.05%)

13:51
04/25/19
04/25
13:51
04/25/19
13:51
Recommendations
Core Laboratories analyst commentary at Stifel »

Core Laboratories…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 30

    Apr

  • 01

    May

AVP

Avon Products

$3.13

0.175 (5.92%)

13:49
04/25/19
04/25
13:49
04/25/19
13:49
Periodicals
Natura said to be in advanced talks to acquire Avon, Valor Economico says »

Natura is in advanced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    May

  • 16

    May

DLPH

Delphi Technologies

$22.60

-2 (-8.13%)

13:45
04/25/19
04/25
13:45
04/25/19
13:45
Options
Delphi call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    May

ADTN

Adtran

$17.39

-0.38 (-2.14%)

13:40
04/25/19
04/25
13:40
04/25/19
13:40
Earnings
Adtran VP Roger Shannon sold over $100K in company shares »

Adtran VP Roger Shannon…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    May

  • 08

    May

AVYA

Avaya

$20.22

0.895 (4.63%)

13:34
04/25/19
04/25
13:34
04/25/19
13:34
Periodicals
Mitel offering to combine with Avaya in stock deal worth over $2B, WSJ says »

Avaya is in talks to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    May

TECK.B

Teck Corp.

$0.00

(0.00%)

13:34
04/25/19
04/25
13:34
04/25/19
13:34
Conference/Events
Teck Corp. management to meet with B.Riley FBR »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Apr

CWT

California Water Service

$49.43

-0.57 (-1.14%)

13:32
04/25/19
04/25
13:32
04/25/19
13:32
Upgrade
California Water Service rating change at Wells Fargo »

California Water Service…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

BHC

Bausch Health

$23.18

0.16 (0.70%)

13:30
04/25/19
04/25
13:30
04/25/19
13:30
Hot Stocks
Breaking Hot Stocks news story on Bausch Health »

Bausch Health trading…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    May

  • 06

    May

  • 06

    May

AVYA

Avaya

$20.20

0.875 (4.53%)

13:28
04/25/19
04/25
13:28
04/25/19
13:28
Periodicals
Mitel offers to combine with Avaya in stock deal, WSJ says »

Mitel's bid values…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    May

CLVS

Clovis

$19.43

-0.4 (-2.02%)

13:25
04/25/19
04/25
13:25
04/25/19
13:25
Options
Clovis call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    May

  • 31

    May

AGN

Allergan

$140.66

0.98 (0.70%)

, TEVA

Teva

$15.07

0.065 (0.43%)

13:25
04/25/19
04/25
13:25
04/25/19
13:25
Conference/Events
Piper Jaffray specialty pharma analysts to hold analyst/industry conference call »

Specialty Pharmaceuticals…

AGN

Allergan

$140.66

0.98 (0.70%)

TEVA

Teva

$15.07

0.065 (0.43%)

ALDR

Alder Biopharmaceuticals

$13.95

0.29 (2.12%)

AMGN

Amgen

$179.82

1.56 (0.88%)

BHVN

Biohaven Pharmaceutical

$62.30

-0.855 (-1.35%)

LLY

Eli Lilly

$117.99

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 28

    Apr

  • 28

    Apr

  • 30

    Apr

  • 30

    Apr

  • 02

    May

  • 03

    May

  • 04

    May

  • 06

    May

  • 07

    May

  • 07

    May

  • 08

    May

  • 09

    May

  • 18

    May

  • 21

    May

  • 29

    May

  • 31

    May

  • 05

    Jun

ZM

Zoom Video

$64.49

1.175 (1.86%)

13:21
04/25/19
04/25
13:21
04/25/19
13:21
Hot Stocks
Zoom, Slack announce new partnership »

Zoom and Slack have…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.